AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01972789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
Study NCT01493856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cresto
Description: tablet, rosuvastatin 20mg
Study NCT01493856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmetec
Description: tablet, olmesartan medoxomil(CS-866) 40mg
Study NCT01493856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1276
Description: tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
Study NCT01853956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Description: Reference product
Study NCT01853956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Description: Test product
Study NCT03984656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine treatment
Description: The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
Study NCT03984656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serratus plane block treatment
Description: The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block.
Study NCT01685021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR00208 (formerly Xmab5574)
Study NCT03305328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
Study NCT01531712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 / / 40mg/m2
Study NCT01531712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy
Study NCT06484361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
Study NCT06484361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2
Description: all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
Study NCT01531712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 100mg/day
Study NCT01531712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100mg/m2 (only in QT)
Study NCT03822208 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AL003
Description: Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort
Study NCT03442296 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner (if applicable)
Study NCT03442296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner (if applicable)
Study NCT03822208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
Study NCT04734509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silhouette breathing system
Description: The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
Study NCT03190655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aluminaid
Description: Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
Study NCT03190655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Hydrogel based wound dressing
Study NCT01588691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eon-mini IPG (implantable pulse generator)
Description: programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
Study NCT01588691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eon-mini IPG (implantable pulse generator)
Description: programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
Study NCT01588691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eon-mini IPG (implantable pulse generator)
Description: programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
Study NCT04022096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 25mg QD
Description: Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
Study NCT04022096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15mg QD
Description: Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
Study NCT01997515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
Study NCT01047709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional therapy including the use of a special pillow
Description: Avoidance of supine sleep via a special pillow and other measures.
Study NCT00071500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSignals™
Description: An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
Study NCT01997515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group P (placebo) will receive the same amount of saline.
Study NCT03369054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minority Stress Treatment
Description: The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?).
Study NCT03369054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As usual
Description: Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
Study NCT02393365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
Study NCT01203228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS
Study NCT02393365 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HCV serology
Description: In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation.
Study NCT01970436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Prenatal Care
Description: Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
Study NCT03442296 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study NCT03442296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study NCT01266811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo, Velcade and dexamethasone
Description: Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
Study NCT01266811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab, Velcade and dexamethasone
Description: Given in 21-day treatment cycles
Study NCT01018069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEG35156
Description: 2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
Study NCT01018069 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: AEG35156
Description: 2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
Study NCT01969604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Lifestyle Counselling
Description: The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand.
Study NCT02201199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine U200 HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT02201199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine U500 HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT02201199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine U100 HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT02993640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin + nitro
Description: vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
Study NCT00959192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
Study NCT00959192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QS-21
Description: IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
Study NCT00959192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QS-21
Description: IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
Study NCT01724164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
Study NCT01724164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic assisted therapy
Description: This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
Study NCT01724164 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Robotic Rehabilitation with PI
Description: The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
Study NCT01724164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation with FES
Description: This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
Study NCT01724164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
Study NCT00171964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid in combination with therapy
Study NCT00101790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pamidronate
Description: There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
Study NCT03561220 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care IMRT (Photon)
Description: As this trial is pragmatic, all treatment will be standard of care.
Study NCT03561220 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Proton Therapy
Description: As this trial is pragmatic, all treatment will be standard of care.
Study NCT03561220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Arm 1: Standard Proton Therapy
Description: 78.0 Gy (RBE) in 39 fractions
Study NCT03561220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Arm 2: Hypofractionated Proton Therapy
Description: 60.0 Gy (RBE) in 20 fractions
Study NCT03364114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoRotor Mucosal Resection System
Description: The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
Study NCT03364114 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continued Ablation
Description: Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
Study NCT01029691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: Women will use positive airway pressure until delivery
Study NCT02672982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTPSY treatment
Description: The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
Study NCT02672982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NUT treatment
Description: Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
Study NCT01203228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myeloablative conditioning
Description: Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW
Study NCT01523886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
Study NCT00661362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Oral tablet, once daily for 24 weeks
Study NCT00661362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, once daily for 24 weeks
Study NCT00661362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet, once daily for 24 weeks
Study NCT00661362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: oral tablet, once daily for 24 weeks
Study NCT00679354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT00679354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00679354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00775138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 280 mg Arikayce™
Description: Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study NCT00775138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Cohort 1
Description: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study NCT00775138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 560 mg Arikayce™
Description: Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study NCT01523886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: Intravenous use: 0,3 mg/kg followed by NaCl-infusion
Study NCT01746927 — intervention group
Intervention type: OTHER
Intervention: Glidescope Cricoid pressure
Description: The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
Study NCT02758327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraTears Lubricating Eye Drops
Description: Sodium Carboxy-methylcellulose 0.25% eye Lubricant
Study NCT01673035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, exposure and response prevention
Description: This intervention entails different exercises aimed exposure to health anxiety stimuli.